Chemicals and Drugs Commons^™

Suvorexant, A Novel Dual Orexin Receptor Antagonist, For The Management Of Insomnia., Andrew H. Han, Carolin R. Burroughs, Evan P. Falgoust, Jamal Hasoon, Grace Hunt, Juyeon Kakazu, Tim Lee, Adam M. Kaye, Alan D. Kaye, Latha Ganti

School of Pharmacy Faculty Articles

PURPOSE OF REVIEW: The present investigation is a comprehensive review regarding the use of Suvorexant for insomnia treatment. It covers the background, pathophysiology, and significance of addressing insomnia, the pharmaceutical details of Suvorexant, and its safety, efficacy, and implications in treating insomnia. We further discuss Suvorexant's role in targeting insomnia with other comorbidities.

RECENT FINDINGS: Insomnia refers to poor quality and/or quantity of sleep. While there are many existing treatments such as benzodiazepines, melatonin agonists, TCAs, and atypical antipsychotics used to target various receptors involved in normal induction and maintenance of sleep, Suvorexant is an antagonist that specifically targets orexin …

Headache And Its Association With Adhd/Add And Stimulant Medication, Claire Nitzsche

Honors Scholar Theses

Years of research has shown that headache (in terms of frequency, duration, and severity) is perpetuated by dysregulation of lifestyle behaviors such as sleep habits, eating habits, level of stress, physical activity etc. Our project aims to explore the potential combined and independent impacts that having ADHD/ADD and taking stimulant drugs have on disrupting one’s lifestyle and examine whether dysregulated lifestyle behaviors contribute to one’s headache experience. No research has investigated how both ADHD/ADD and stimulant drug use effect headache experience. In this cross-sectional study, 177 UConn undergraduate students completed a 10-minute survey regarding lifestyle behaviors and headache experience. Participants …

Why We Can't Sleep, Gayle Greene

Scripps Faculty Publications and Research

Can't sleep? Well you're not alone, especially among women. A 2007 poll by the National Sleep Foundation found that 67 percent of women frequently experience sleep problems and 29 percent use some type of sleep aid at least a few nights a week. Other surveys have consistently found that nearly half again as many women as men complain of insomnia.

Urotensin Ii Modulates Rapid Eye Movement Sleep Through Activation Of Brainstem Cholinergic Neurons, Salvador Huitron-Resendiz, Morten P. Kristensen, Stephen L. Grupke, Christopher Tyler, Olivier Civelli, Christopher S. Leonard, Luis De Lecea

NYMC Faculty Publications

Urotensin II (UII) is a cyclic neuropeptide with strong vasoconstrictive activity in the peripheral vasculature. UII receptor mRNA is also expressed in the CNS, in particular in cholinergic neurons located in the mesopontine tegmental area, including the pedunculopontine tegmental (PPT) and lateral dorsal tegmental nuclei. This distribution suggests that the UII system is involved in functions regulated by acetylcholine, such as the sleep-wake cycle. Here, we tested the hypothesis that UII influences cholinergic PPT neuron activity and alters rapid eye movement (REM) sleep patterns in rats. Local administration of UII into the PPT nucleus increases REM sleep without inducing changes …